MCID: FLL027
MIFTS: 67

Fallopian Tube Carcinoma

Categories: Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Fallopian Tube Carcinoma

MalaCards integrated aliases for Fallopian Tube Carcinoma:

Name: Fallopian Tube Carcinoma 12 54 15 17 71
Fallopian Tube Cancer 12 52 36 54 15
Cancer of the Fallopian Tube 12 52
Carcinoma of Fallopian Tube 12 29
Neoplasm of Fallopian Tube 12 29
Fallopian Tube Neoplasms 43 71
Malignant Neoplasm of Fallopian Tube 71
Malignant Neoplasm of Uterine Tube 12
Malignant Tumour of Fallopian Tube 12
Malignant Tumor of Fallopian Tubes 58
Malignant Tumor of Fallopian Tube 12
Tumor, Fallopian Tube, Malignant 12
Tumor of the Fallopian Tube 12
Cancer of Fallopian Tubes 58
Fallopian Tube Neoplasm 12
Malignant Tubal Tumor 58
Fallopian Tube Ca 12
Tubal Cancer 58

Characteristics:

Orphanet epidemiological data:

58
malignant tumor of fallopian tubes
Prevalence: 1-9/100000 (Europe);

Classifications:

Orphanet: 58  
Rare gynaecological and obstetric diseases


External Ids:

Disease Ontology 12 DOID:1963 DOID:1964
KEGG 36 H01554
ICD9CM 34 183.2
MeSH 43 D005185
SNOMED-CT 67 93794008
ICD10 32 C57.0
ICD10 via Orphanet 33 C57.0
UMLS via Orphanet 72 C0153579 C0238122
Orphanet 58 ORPHA180242
UMLS 71 C0015558 C0153579 C0238122

Summaries for Fallopian Tube Carcinoma

NIH Rare Diseases : 52 Fallopian tube cancer develops in the tubes that connect a woman's ovaries and uterus . It is very rare and accounts for only 1-2% of all gynecologic cancers . Fallopian tube cancer occurs when normal cells in one or both tubes change and grow in an uncontrolled way, forming a mass called a tumor . Cancer can begin in any of the different cell types that make up the fallopian tubes. The most common type is called adenocarcinoma (a cancer of cells from glands). Leiomyosarcoma (a cancer of smooth muscle cells) and transitional cell carcinoma (a cancer of the cells lining the fallopian tubes) are more rare. While some fallopian tube cancers actually begin in the tubes themselves, fallopian tube cancer is more often the result of cancer spreading from other parts of the body to the tubes. For example, the fallopian tubes are a common site of metastasis (spread) of cancers that started in the ovaries, uterus, endometrium, (the tissue lining the uterus) appendix, or colon. Women with fallopian tube cancer may experience symptoms, although some affected women may have no symptoms at all. The signs of fallopian tube cancer are often non-specific, meaning that they can also be signs of other medical conditions that are not cancer. Signs and symptoms of fallopian tube cancer can include: irregular or heavy vaginal bleeding (especially after menopause); occasional abdominal or pelvic pain or feeling of pressure; vaginal discharge that may be clear, white, or tinged with blood; and a pelvic mass or lump. Doctors use many tests to diagnose cancer of the fallopian tubes. Some of these tests may include: pelvic examination, transvaginal ultrasound , a blood test that measures the tumor marker CA-125, computed tomography (CT or CAT) scan , and magnetic resonance imaging (MRI) . Fallopian tube cancer can be best treated when detected early. If the cancer has spread to the walls of the tubes or outside of the tubes, then there is a lower chance that the disease can be treated successfully. The stage of the cancer determines the type of treatment needed. Most women will need surgery and some will go on to have chemotherapy and/or radiation therapy .

MalaCards based summary : Fallopian Tube Carcinoma, also known as fallopian tube cancer, is related to fallopian tube carcinosarcoma and cystadenocarcinoma. An important gene associated with Fallopian Tube Carcinoma is BRCA1 (BRCA1 DNA Repair Associated), and among its related pathways/superpathways are Gene Expression and GPCR Pathway. The drugs Olaparib and Poly(ADP-ribose) Polymerase Inhibitors have been mentioned in the context of this disorder. Affiliated tissues include fallopian tube, breast and ovary, and related phenotypes are Decreased viability in esophageal squamous lineage and Decreased homologous recombination repair frequency

Disease Ontology : 12 A female reproductive organ cancer that is located in fallopian tube.

KEGG : 36 Fallopian tube cancer is a rare, aggressive gynecologic malignancy. Recent genetic and immunohistochemical studies strongly suggest that high-grade serous adenocarcinoma (SAC) involving the ovary likely arises from distal fallopian tube epithelium, indicating that some ovarian cancers develop in the fallopian tube and are then spread to the ovary. Fallopian tube cancers are similar to ovarian cancer with respect to the proportion of tumors with abnormal expression of c-erbB-2 and p53. It has been proposed that the p53 signature is the earliest step in the pathogenesis of fallopian tube cancer. In this model, tubal epithelium on the fimbria experiences genotoxic damage and, as a result, the secretory cell exhibits over-accumulation of p53 protein (p53 signature). There is also some evidence that BRCA-1 and BRCA-2 mutations and c-myc have a major role in tumorgenesis.

Wikipedia : 74 Primary fallopian tube cancer (PFTC), often just tubal cancer, is a malignant neoplasm that originates... more...

Related Diseases for Fallopian Tube Carcinoma

Diseases related to Fallopian Tube Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 385)
# Related Disease Score Top Affiliating Genes
1 fallopian tube carcinosarcoma 32.5 WT1 TP53
2 cystadenocarcinoma 30.7 VEGFA TP53 PGR ERBB2
3 inflammatory breast carcinoma 30.6 PGR ESR1 ERBB2
4 intravenous leiomyomatosis 30.6 PGR ESR1
5 primary peritoneal carcinoma 30.5 VEGFA TP53 PGR ERBB2 BRCA2 BRCA1
6 papillary adenocarcinoma 30.3 TP53 PGR ERBB2 BRCA2 BRCA1
7 leiomyomatosis 30.3 WT1 PGR ESR1
8 breast fibroadenoma 30.2 TP53 PGR ESR1 ERBB2 BRCA1
9 mucinous adenocarcinoma 30.2 VEGFA TP53 PGR ESR1 ERBB2
10 fallopian tube endometrioid adenocarcinoma 30.2 RAD51C PAX8 ERBB2
11 endometriosis of ovary 30.1 PTEN PGR ESR1
12 papillary carcinoma 30.1 PGR PAX8 ESR1 ERBB2
13 leiomyosarcoma 29.9 WT1 VEGFA TP53 PGR ESR1
14 cystadenoma 29.9 PTEN PGR BRCA1
15 estrogen-receptor positive breast cancer 29.7 VEGFA TP53 PGR MYC ESR1 ERBB2
16 endometriosis 29.6 VEGFA PTEN PGR MMP2 ESR1
17 papillary serous adenocarcinoma 29.5 WT1 TP53 PGR PAX8 BRCA2 BRCA1
18 benign mesothelioma 29.5 WT1 PAX8
19 in situ carcinoma 29.4 TP53 PTEN PGR MYC ESR1 ERBB2
20 rhabdomyosarcoma 29.4 VEGFA TP53 PTEN MYC BRCA1
21 endometrial adenocarcinoma 29.3 VEGFA TP53 PTEN PGR ESR1 ERBB2
22 uterine carcinosarcoma 29.3 VEGFA TP53 PTEN PGR ESR1 ERBB2
23 adenocarcinoma 28.9 VEGFA TP53 PTEN MYC MMP2 ERBB2
24 squamous cell carcinoma 28.9 VEGFA TP53 PTEN MYC MMP2 ERBB2
25 carcinosarcoma 28.9 WT1 TP53 PTEN PGR PAX8 ERBB2
26 cervical cancer 28.6 VEGFA TP53 PTEN MYC MMP2 ESR1
27 bladder cancer 28.4 VEGFA TP53 PTEN MYC MMP2 ERBB2
28 serous cystadenocarcinoma 28.3 WT1 VEGFA TP53 PTEN PGR PAX8
29 ovarian serous cystadenocarcinoma 28.2 VEGFA TP53 PTEN PGR PAX8 MYC
30 wilms tumor 1 28.1 WT1 VEGFA TP53 PGR PAX8 PALB2
31 endometrial cancer 27.2 WT1 VEGFA TP53 PTEN PGR PAX8
32 breast cancer 25.9 WT1 VEGFA TP53 RAD51D RAD51C PTEN
33 ovarian cancer 25.9 WT1 WFDC2 VEGFA TP53 RAD51D RAD51C
34 familiar fallopian tube carcinoma 12.5
35 fallopian tube adenocarcinoma 11.7
36 fallopian tube adenosarcoma 11.4
37 fallopian tube transitional cell carcinoma 11.4
38 fallopian tube squamous cell carcinoma 11.4
39 fallopian tube leiomyosarcoma 11.4
40 fallopian tube germ cell cancer 11.4
41 ovarian epithelial cancer 10.6
42 hereditary site-specific ovarian cancer syndrome 10.6 BRCA2 BRCA1
43 gastric papillary adenocarcinoma 10.6 TP53 ERBB2
44 scirrhous adenocarcinoma 10.6 PGR ERBB2
45 rare malignant breast tumor 10.6 BRCA2 BRCA1
46 bartholin's gland adenoid cystic carcinoma 10.6 PGR ESR1
47 chronic tympanitis 10.6 PGR ESR1
48 granulomatous endometritis 10.5 PGR ESR1
49 lipid-rich breast carcinoma 10.5 PGR ERBB2
50 breast squamous cell carcinoma 10.5 TP53 ERBB2

Comorbidity relations with Fallopian Tube Carcinoma via Phenotypic Disease Network (PDN):


Ovarian Cancer

Graphical network of the top 20 diseases related to Fallopian Tube Carcinoma:



Diseases related to Fallopian Tube Carcinoma

Symptoms & Phenotypes for Fallopian Tube Carcinoma

GenomeRNAi Phenotypes related to Fallopian Tube Carcinoma according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 10.07 BRCA1 BRCA2 CDKN1B ERBB2 ESR1 MMP2
2 Decreased homologous recombination repair frequency GR00151-A-1 9.98 BARD1 BRCA1
3 Decreased homologous recombination repair frequency GR00151-A-2 9.98 BRCA1
4 Decreased homologous recombination repair frequency GR00236-A-3 9.98 BARD1 BRCA1 BRCA2 PALB2
5 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.84 BARD1 BRCA1 BRCA2 PALB2 PARP2 PTEN
6 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.84 BARD1 BRCA1 BRCA2 PALB2 PARP2 PTEN
7 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.81 BARD1 BRCA1 BRCA2 CDKN1B PALB2 PARP2
8 Increased cell death HMECs cells GR00103-A-0 9.73 BRCA1 MYC PGR PTEN RAD51C TP53
9 Decreased viability with cisplatin GR00101-A-4 9.5 BARD1 BRCA1 BRCA2
10 Decreased sensitivity to paclitaxel GR00112-A-0 9.4 PTEN WT1
11 Synthetic lethal with cisplatin GR00101-A-1 9.13 BARD1 BRCA1 BRCA2

MGI Mouse Phenotypes related to Fallopian Tube Carcinoma:

45 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.51 BARD1 BRCA1 BRCA2 CDKN1B ERBB2 ESR1
2 embryo MP:0005380 10.51 BARD1 BRCA1 BRCA2 CDKN1B ERBB2 ESR1
3 growth/size/body region MP:0005378 10.5 BARD1 BRCA1 BRCA2 CDKN1B ERBB2 ESR1
4 cardiovascular system MP:0005385 10.49 BRCA1 CDKN1B ERBB2 ESR1 MMP2 MYC
5 mortality/aging MP:0010768 10.47 BARD1 BRCA1 BRCA2 CDKN1B ERBB2 ESR1
6 homeostasis/metabolism MP:0005376 10.42 BRCA1 BRCA2 CDKN1B ERBB2 ESR1 MMP2
7 behavior/neurological MP:0005386 10.4 BRCA1 BRCA2 CDKN1B ERBB2 ESR1 MYC
8 endocrine/exocrine gland MP:0005379 10.39 BRCA1 BRCA2 CDKN1B ERBB2 ESR1 MYC
9 hematopoietic system MP:0005397 10.37 BRCA1 BRCA2 CDKN1B ESR1 MMP2 MYC
10 neoplasm MP:0002006 10.33 BARD1 BRCA1 BRCA2 CDKN1B ERBB2 ESR1
11 immune system MP:0005387 10.31 BRCA1 BRCA2 CDKN1B ESR1 MMP2 MYC
12 limbs/digits/tail MP:0005371 10.29 BRCA1 BRCA2 ERBB2 ESR1 MYC PALB2
13 nervous system MP:0003631 10.28 BARD1 BRCA1 BRCA2 CDKN1B ERBB2 ESR1
14 integument MP:0010771 10.26 BRCA1 BRCA2 CDKN1B ERBB2 ESR1 MYC
15 digestive/alimentary MP:0005381 10.24 BRCA1 BRCA2 CDKN1B ERBB2 ESR1 MYC
16 muscle MP:0005369 10.22 BRCA1 CDKN1B ERBB2 ESR1 MMP2 MYC
17 normal MP:0002873 10.18 BARD1 BRCA1 BRCA2 ERBB2 ESR1 MMP2
18 craniofacial MP:0005382 10.14 CDKN1B ERBB2 MMP2 MYC PAX8 TP53
19 no phenotypic analysis MP:0003012 10.01 CDKN1B ESR1 MYC PAX8 PGR TP53
20 reproductive system MP:0005389 10 BRCA1 BRCA2 CDKN1B ERBB2 ESR1 MYC
21 renal/urinary system MP:0005367 9.86 BRCA1 CDKN1B ESR1 PAX8 PTEN TP53
22 pigmentation MP:0001186 9.72 BRCA1 CDKN1B MYC PTEN TP53
23 respiratory system MP:0005388 9.61 BRCA1 CDKN1B ERBB2 ESR1 MMP2 PTEN
24 skeleton MP:0005390 9.4 BRCA1 BRCA2 CDKN1B ERBB2 ESR1 MMP2

Drugs & Therapeutics for Fallopian Tube Carcinoma

Drugs for Fallopian Tube Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 368)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Olaparib Approved Phase 4 763113-22-0 23725625
2 Poly(ADP-ribose) Polymerase Inhibitors Phase 4
3
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
4
Cisplatin Approved Phase 2, Phase 3 15663-27-1 84093 441203 2767
5
Ifosfamide Approved Phase 2, Phase 3 3778-73-2 3690
6
Sodium citrate Approved, Investigational Phase 3 68-04-2
7
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
8
Epirubicin Approved Phase 3 56420-45-2 41867
9
Alvimopan Approved, Investigational Phase 3 156053-89-3 5488548
10
Octreotide Approved, Investigational Phase 3 83150-76-9 383414 6400441
11
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
12
Durvalumab Approved, Investigational Phase 3 1428935-60-7
13
nivolumab Approved Phase 3 946414-94-4
14
Trabectedin Approved, Investigational Phase 3 114899-77-3 108150
15
Rucaparib Approved, Investigational Phase 3 283173-50-2 9931954
16
leucovorin Approved Phase 3 58-05-9 6006 143
17
Topotecan Approved, Investigational Phase 3 119413-54-6, 123948-87-8 60700
18
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
19
Letrozole Approved, Investigational Phase 3 112809-51-5 3902
20
Selenium Approved, Investigational, Vet_approved Phase 3 7782-49-2
21
Selenious acid Approved, Investigational Phase 3 7783-00-8
22
Bevacizumab Approved, Investigational Phase 2, Phase 3 216974-75-3
23
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
24
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
25
Tyrosine Approved, Investigational, Nutraceutical Phase 3 60-18-4 6057
26
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 3 65-23-6 1054
27
Dehydroepiandrosterone Approved, Investigational, Nutraceutical Phase 3 53-43-0 9860744
28
Glutamic acid Approved, Nutraceutical Phase 3 56-86-0 33032
29
Saracatinib Investigational Phase 2, Phase 3 379231-04-6
30 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
31 Paclitaxel poliglumex Experimental, Investigational Phase 3 263351-82-2
32
Cediranib Investigational Phase 3 288383-20-0 9933475
33
Maleic acid Experimental, Investigational Phase 3 110-17-8, 110-16-7 444972
34
Trebananib Investigational Phase 3 894356-79-7
35
Fosbretabulin Investigational Phase 2, Phase 3 222030-63-9 5351387
36 Combretastatin Investigational Phase 2, Phase 3 82855-09-2
37 Albumin-Bound Paclitaxel Phase 3
38 Antimitotic Agents Phase 3
39
Isophosphamide mustard Phase 2, Phase 3 0
40 Citrate Phase 3
41
Erlotinib Hydrochloride Phase 3 183319-69-9 176871
42 Analgesics Phase 3
43 Epothilone B Phase 3
44 Liver Extracts Phase 3
45 Narcotics Phase 3
46 Anesthetics Phase 3
47 Anesthetics, General Phase 3
48 Analgesics, Opioid Phase 3
49 Adjuvants, Anesthesia Phase 3
50 Central Nervous System Depressants Phase 3

Interventional clinical trials:

(show top 50) (show all 638)
# Name Status NCT ID Phase Drugs
1 An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed Somatic or Germline BRCA Mutated Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy (ORZORA). Active, not recruiting NCT02476968 Phase 4 Olaparib
2 A Randomized Phase II/III Trial Comparing Carboplatin-Ifosfamide (IC)-Chemotherapy Vs. IC-Chemotherapy Combined With Extreme Whole Body Hyperthermia In Patients With Recurrence Of Epithelial Ovarian Carcinoma: DOLPHIN-1-STUDY Unknown status NCT00045461 Phase 2, Phase 3 carboplatin;ifosfamide
3 Randomized Phase III Trial of Conventional Paclitaxel and Carboplatin Versus Dose Dense Weekly Paclitaxel and Carboplatin in Patients With Newly Diagnosed Stage II-IV Mullerian Carcinoma Unknown status NCT00226915 Phase 3 Paclitaxel+Carboplatin;Paclitaxel+Carboplatin
4 Cytoreduction With or Without Intraoperative Intraperitoneal Hyperthermic Chemotherapy (HIPEC) in Patients With Peritoneal Carcinomatosis From Ovarian Cancer, Fallopian Tube or Primary Peritoneal Carcinoma : Randomized Clinical Trial. Unknown status NCT02328716 Phase 3 Hipec with Cisplatin
5 An International Phase III Randomised Trial of Dose Fractionated Chemotherapy Compared to Standard Three Weekly Chemotherapy, Following Immediate Primary Surgery or as Part of Delayed Primary Surgery, for Women With Newly Diagnosed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Unknown status NCT01654146 Phase 3 Carboplatin;Carboplatin;Paclitaxel;Paclitaxel
6 A Randomised, Placebo-controlled, Trial of Concurrent Cediranib [AZD2171] (With Platinum-based Chemotherapy) and Concurrent and Maintenance Cediranib in Women With Platinum-sensitive Relapsed Ovarian Cancer Unknown status NCT00532194 Phase 3 cediranib
7 A Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Ifosfamide Plus Paclitaxel in Chemotherapy-Naive Patients With Newly Diagnosed Stage I-IV, Persistent or Recurrent Carcinosarcoma (Mixed Mesodermal Tumors) of the Uterus, Fallopian Tube, Peritoneum or Ovary Unknown status NCT00954174 Phase 3 Carboplatin;Ifosfamide;Paclitaxel
8 The Phase II Study of Intraoperative Hyperthermic Intraperitoneal Chemotherapy Followed by Intravenous Chemotherapy in Patients With Ovarian Cancer Unknown status NCT01091636 Phase 2, Phase 3
9 Stage IIIC Unresectable Epithelial Ovarian/Tubal Cancer With Partial or Complete Response After 1st Line Neoadjuvant Chemotherapy (3 Cycles CBDCA+Paclitaxel): a Phase 3 Prospective Randomized Study Comparing Cytoreductive Surgery + Hyperthermic Intraperitoneal Chemotherapy (CDDP+Paclitaxel) + 3 Cycles CBDCA+Paclitaxel vs Cytoreductive Surgery Alone + 3 Cycles CBDCA+Paclitaxel. Unknown status NCT01628380 Phase 3
10 A Randomized Feasibility Trial to Determine the Impact of Timing of Surgery and Chemotherapy in Newly Diagnosed Patients With Advanced Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Carcinoma Completed NCT00075712 Phase 2, Phase 3 carboplatin;paclitaxel
11 A Randomized Study Of Tamoxifen Versus Thalidomide (NSC# 66847) In Patients With Biochemical-Recurrence-Only Epithelial Ovarian Cancer, Cancer Of The Fallopian Tube, And Primary Peritoneal Carcinoma After First Line Chemotherapy Completed NCT00041080 Phase 3 tamoxifen citrate;thalidomide
12 A Randomized Phase III Study Comparing Upfront Debulking Surgery Versus Neo-Adjuvant Chemotherapy in Patients With Stage IIIC or IV Epithelial Ovarian Carcinoma Completed NCT00003636 Phase 3 carboplatin;cisplatin
13 A Phase III, Multicenter, Randomized, Blinded, Placebo-controlled Trial of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Platinum-sensitive Recurrent Ovary, Primary Peritoneal, or Fallopian Tube Carcinoma Completed NCT00434642 Phase 3 Carboplatin;Gemcitabine;Bevacizumab;Placebo
14 A Phase 3, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers Completed NCT01204749 Phase 3 AMG 386;AMG 386 Placebo;Paclitaxel;Paclitaxel
15 A Randomized, Multicenter, Phase III Study of Erlotinib Versus Observation in Patients With no Evidence of Disease Progression After First Line, Platinum-Based Chemotherapy For High-Risk Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT00263822 Phase 3 erlotinib hydrochloride
16 A Randomized, Parallel Group, Open-label, Active Controlled, Multicenter Phase III Trial of Patupilone (EPO906) Versus Pegylated Liposomal Doxorubicin in Taxane/Platinum Refractory/Resistant Patients With Recurrent Epithelial Ovarian, Primary Fallopian or Primary Peritoneal Cancer Completed NCT00262990 Phase 3 EPO906 (Patupilone);doxorubicin
17 Multi-Center, Randomized, Double-Blind, Phase III Efficacy Study Comparing Phenoxodiol in Combination With Carboplatin Versus Carboplatin With Placebo in Patients With Platinum-Resistant or Platinum-Refractory Late-Stage Epithelial Ovarian, Fallopian or Primary Peritoneal Cancer Following at Least Second Line Platinum Therapy Completed NCT00382811 Phase 3 phenoxodiol;carboplatin;placebo
18 A Multi-National Randomized Phase-III GCIG Intergroup-Study Comparing 1st-line Chemotherapy With Gemcitabine/Paclitaxel/Carboplatin vs Paclitaxel/Carboplatin In Previously Untreated Patients With Epithelial Ovarian Cancer FIGO Stages I-IV Completed NCT00052468 Phase 3 TCG;TC
19 ICON7 - A Randomised, Two-Arm, Multi-Centre Gynaecologic Cancer InterGroup Trial of Adding Bevacizumab to Standard Chemotherapy (Carboplatin and Paclitaxel) in Patients With Epithelial Ovarian Cancer Completed NCT00483782 Phase 3 carboplatin;paclitaxel
20 A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Completed NCT01846611 Phase 3 Trabectedin;DOXIL;Dexamethasone;DOXIL
21 Early Post-Operative Enteral Feeding in Patients With Advanced Epithelial Ovarian Cancer Completed NCT00850772 Phase 3
22 A Phase III Study of Cisplatin Plus Topotecan Followed by Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Carboplatin as First Line Chemotherapy in Women With Newly Diagnosed Advanced Epithelial Ovarian Cancer Completed NCT00028743 Phase 3 carboplatin;cisplatin;paclitaxel;topotecan hydrochloride
23 An Open, Randomized, Multicenter Study in Patients With Recurrent Epithelian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer to Compare the Efficay and Safety of Paclitaxel (Micellar) Nanoparticles and Paclitaxel (Cremophor® EL) Completed NCT00989131 Phase 3 Paclical®;Taxol®
24 Phase III Randomized Trial of Induction Chemotherapy With Gemcitabine and Carboplatin Followed by Elective Paclitaxel Consolidation Versus Paclitaxel and Carboplatin Followed by Elective Paclitaxel Consolidation in Patients With Primary Epithelial Ovarian, Primary Peritoneal Cancer or Fallopian Tube Carcinoma Completed NCT00191646 Phase 3 Gemcitabine;Paclitaxel;Carboplatin
25 Phase III Multicenter Study in Epithelial Ovarian Carcinoma FIGO Stage IIB-IV Comparing Treatment With Paclitaxel and Carboplatin to Paclitaxel and Carboplatin Sequentially Followed by Topotecan Completed NCT00006454 Phase 3 carboplatin;paclitaxel;topotecan hydrochloride
26 SCOTROC 4: A Prospective, Multicentre, Randomised Trial Of Carboplatin Flat Dosing Vs Intrapatient Dose Escalation In First Line Chemotherapy Of Ovarian, Fallopian Tube And Primary Peritoneal Cancers Completed NCT00098878 Phase 3 carboplatin
27 Phase III Randomized Trial of 12 Months vs. 3 Months of Paclitaxel in Patients With Advanced Ovarian Cancer Who Attain a Clinically Defined Complete Response (CR) Following Platinum/Paclitaxel-Based Chemotherapy Completed NCT00003120 Phase 3 paclitaxel
28 A Randomised Trial in Relapsed Ovarian Cancer: Early Treatment Based on CA 125 Levels Alone Vs. Delayed Treatment Based On Conventional Clinical Indicators Completed NCT00002895 Phase 3 chemotherapy
29 A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Completed NCT00262847 Phase 3 Carboplatin;Paclitaxel
30 A Randomized Trial of Paclitaxel/Epirubicin/Carboplatin Combination (TEC) Versus Paclitaxel/Carboplatin (TC) in the Treatment of Women With Advanced Ovarian Cancer Completed NCT00004934 Phase 3 carboplatin;epirubicin hydrochloride;paclitaxel
31 A Double-Blind Randomized Trial of Pyridoxine Versus Placebo for the Prevention of Doxil-Related Palmar-Plantar Erythrodysesthesia (Hand-Foot Syndrome) Completed NCT00245050 Phase 3 Placebo;doxorubicin HCL liposome
32 The Use of Glutathione (GSH) for Prevention of Paclitaxel/Carboplatin (TAXOL/CBDCA) Induced Peripheral Neuropathy: A Phase III Randomized, Double-Blind Placebo Controlled Study Completed NCT02311907 Phase 3 Carboplatin;Glutathione;Paclitaxel
33 Accelerating Gastrointestinal Recovery in Women Undergoing Staging and/or Debulking Surgery for Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma: A Randomized, Double-Blind, Placebo-Controlled Trial Completed NCT01704651 Phase 3 Alvimopan;Placebo
34 Phase III Randomized Study of TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Liposomal Doxorubicin (Doxil) as Second-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer [ASSIST-3] Completed NCT00102973 Phase 3 TLK286 in Combination with Carboplatin;Doxorubicin HCl Liposome Injection
35 Global Study to Assess the Addition of Bevacizumab to Carboplatin and Paclitaxel as Front-line Treatment of Epithelial Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Carcinoma Completed NCT01239732 Phase 3 Paclitaxel;Bevacizumab;Carboplatin
36 A Randomized Phase III Trial of Gemzar Versus Doxil With Crossover Treatment Option for Patients With Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Undergoing Second or Third-Line Chemotherapy Completed NCT00191607 Phase 3 Gemcitabine;liposomal doxorubicin
37 A Randomized Study of Chemotherapy Versus Hormonal Treatment in Patients With Ovarian Cancer Resistant or Refractory to Platinum and Taxane Completed NCT02728622 Phase 3 Tamoxifen;Chemotherapy
38 A Multi-National,Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin and Carboplatin Versus Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse (> 6 Months) Completed NCT00189553 Phase 3 Pegylated liposomal doxorubicin;Carboplatin;Paclitaxel
39 A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have Not Progressed After First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Completed NCT00866697 Phase 3 Pazopanib;Placebo
40 Phase III Double-Blind Study Of Depot Octreotide Versus Placebo In The Prevention Of Acute Diarrhea In Patients Receiving Pelvic Radiation Therapy Completed NCT00033605 Phase 3 octreotide acetate
41 A Randomised Placebo-controlled Trial of Saracatinib (AZD0530) Plus Weekly Paclitaxel in Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer Completed NCT01196741 Phase 2, Phase 3 Paclitaxel;Saracatinib;Matched placebo
42 Vaginal DHEA for Vaginal Symptoms: A Phase III Randomized, Double Blind, Placebo- Controlled Trial Completed NCT01376349 Phase 3 prasterone
43 Application of the Microculture Kinetic (MiCK) Assay for Apoptosis to Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas Completed NCT00443196 Phase 2, Phase 3
44 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
45 Study of Upfront Surgery Versus Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery for Patients With Stage IIIC and IV Ovarian Cancer Recruiting NCT02859038 Phase 3
46 ARIEL4 (Assessment of Rucaparib In Ovarian CancEr TriaL): A Phase 3 Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02855944 Phase 3 Chemotherapy;Rucaparib
47 A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (KEYLYNK-001/ENGOT-ov43) Recruiting NCT03740165 Phase 3 Placebo for pembrolizumab;Carboplatin;Paclitaxel;Olaparib;Placebo for olaparib
48 A Phase III Multicenter Prospective Randomized Controlled Clinical Trial of Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian Cancer After Cytoreductive Surgery Recruiting NCT03373058 Phase 3 adjuvant chemotherapy
49 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase III Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) for Maintenance Treatment in Patients With Platinum-sensitive Relapsed Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer (Collectively Referred to as Ovarian Cancer) Recruiting NCT03705156 Phase 3 ZL-2306(nirapairb);Placebos
50 A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Phase III Clinical Trial Evaluating the Efficacy and Safety of ZL-2306 (Niraparib) for Maintenance Treatment in Patients With Advanced Ovarian Cancer, Fallopian Tube Carcinoma or Primary Peritoneal Cancer (Collectively Referred to as Ovarian Cancer) Who Have Achieved Effective Response After First-line Platinum-containing Chemotherapy Recruiting NCT03709316 Phase 3 ZL-2306 (Nirapairb);Placebo Comparator

Search NIH Clinical Center for Fallopian Tube Carcinoma

Cochrane evidence based reviews: fallopian tube neoplasms

Genetic Tests for Fallopian Tube Carcinoma

Genetic tests related to Fallopian Tube Carcinoma:

# Genetic test Affiliating Genes
1 Neoplasm of Fallopian Tube 29
2 Carcinoma of Fallopian Tube 29

Anatomical Context for Fallopian Tube Carcinoma

The Foundational Model of Anatomy Ontology organs/tissues related to Fallopian Tube Carcinoma:

19
Fallopian Tube

MalaCards organs/tissues related to Fallopian Tube Carcinoma:

40
Breast, Ovary, Testes, T Cells, Colon, Uterus, Appendix

Publications for Fallopian Tube Carcinoma

Articles related to Fallopian Tube Carcinoma:

(show top 50) (show all 702)
# Title Authors PMID Year
1
Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. 54 61
19141781 2009
2
Occult fallopian tube cancer in a patient with BRCA1 breast cancer. 54 61
18971141 2008
3
Microinvasive fimbrial fallopian tube carcinoma in a BRCA-2 mutation carrier. 54 61
18207147 2008
4
Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. 54 61
16835424 2006
5
Follow-up of in situ and early-stage fallopian tube carcinoma in patients undergoing prophylactic surgery for proven or suspected BRCA-1 or BRCA-2 mutations. 54 61
15252324 2004
6
BRCA2 germline mutations in primary cancer of the fallopian tube. 54 61
15254695 2004
7
Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. 54 61
15083174 2004
8
Occult cancer of the fallopian tube in a BRCA2 germline mutation carrier at prophylactic salpingo-oophorectomy. 54 61
14984974 2004
9
[Carcinoma of the fallopian tube after prophylactic laparoscopic ovariectomy in a patient with a BRCAI mutation]. 54 61
12756880 2003
10
Incidental diagnosis of primary fallopian tube carcinoma during prophylactic salpingo-oophorectomy in BRCA2 mutation carrier. 54 61
12504983 2002
11
Pathologic findings in prophylactic oophorectomy specimens in high-risk women. 54 61
12468342 2002
12
Molecular evidence for putative tumour suppressor genes on chromosome 13q specific to BRCA1 related ovarian and fallopian tube cancer. 54 61
12354934 2002
13
Inactivation of BRCA1 and BRCA2 in ovarian cancer. 54 61
12237285 2002
14
Fallopian tube cancer in a BRCA1 mutation carrier: rapid development and failure of screening. 54 61
11810084 2002
15
A genetic epidemiological study of carcinoma of the fallopian tube. 54 61
11263928 2001
16
Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis. 54 61
11161856 2001
17
Germline BRCA2 mutation in a patient with fallopian tube carcinoma: a case report. 54 61
10785486 2000
18
Molecular evidence linking primary cancer of the fallopian tube to BRCA1 germline mutations. 54 61
10620440 2000
19
BRCA1 mutations in familial ovarian cancer. 54 61
10444347 1999
20
A phase II study of the combination chemotherapy of bevacizumab and gemcitabine in women with platinum-resistant recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. 61
32028974 2020
21
Demcizumab combined with paclitaxel for platinum-resistant ovarian, primary peritoneal, and fallopian tube cancer: The SIERRA open-label phase Ib trial. 61
32037195 2020
22
A simple method of quantifying chemotherapy-induced peripheral neuropathy using PainVision PS-2100®. 61
31774247 2020
23
Pathological findings following risk-reducing salpingo-oophorectomy in BRCA mutation carriers: A systematic review and meta-analysis. 61
31521389 2020
24
A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer. 61
31708167 2020
25
Phase II study of everolimus and bevacizumab in recurrent ovarian, peritoneal, and fallopian tube cancer. 61
31739991 2020
26
Metastases to the ovary arising from endometrial, cervical and fallopian tube cancer: recent advances. 61
31846521 2020
27
Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors. 61
31617075 2019
28
Simultaneous germline and somatic sequencing in ovarian carcinoma: mutation rate and impact on clinical decision-making. 61
31883735 2019
29
Diffusion-weighted MRI in Advanced Epithelial Ovarian Cancer: Apparent Diffusion Coefficient as a Response Marker. 61
31573402 2019
30
Detection of early stage ovarian cancer in a large community cohort. 61
31568690 2019
31
Olaparib in the therapy of advanced ovarian cancer: first real world experiences in safety and efficacy from China. 61
31775908 2019
32
Weekly Dose-Dense Paclitaxel and Triweekly Low-Dose Cisplatin: A Well-Tolerated and Effective Chemotherapeutic Regimen for First-Line Treatment of Advanced Ovarian, Fallopian Tube, and Primary Peritoneal Cancer. 61
31795359 2019
33
Metabolic syndrome and risk of ovarian and fallopian tube cancer in the United States: An analysis of linked SEER-Medicare data. 61
31495456 2019
34
TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7). 61
31420412 2019
35
Quality of life outcomes following surgery for advanced ovarian cancer: a systematic review and meta-analysis. 61
31273066 2019
36
Metastatic Fallopian Tube Cancer Detected During Colonoscopy. 61
29730436 2019
37
Unexpected primary fallopian tube carcinoma during gynecological operations: Clinicopathological and prognostic factors analyses of 67 cases. 61
31542083 2019
38
North Korea Must be Global Scale Cohort, Not a Galapagos in the Medical Research Field. 61
31554378 2019
39
BRCA mutation in high grade epithelial ovarian cancers. 61
31467961 2019
40
LESS with Suture Suspension for Early-Stage Adnexa Cancer Staging. 61
31595144 2019
41
Fallopian Tube Carcinoma. 61
31283415 2019
42
The first Japanese nationwide multicenter study of BRCA mutation testing in ovarian cancer: CHARacterizing the cross-sectionaL approach to Ovarian cancer geneTic TEsting of BRCA (CHARLOTTE). 61
31263023 2019
43
Rapidly Changing Landscape of Fallopian Tube Carcinoma. 61
31283416 2019
44
Medical diligence uncovers fallopian tube cancer after abnormal Pap test. 61
31345832 2019
45
Phase II Trial of Chemopreventive Effects of Levonorgestrel on Ovarian and Fallopian Tube Epithelium in Women at High Risk for Ovarian Cancer: An NRG Oncology Group/GOG Study. 61
31015198 2019
46
Evaluation of screening and risk-reducing surgery for women followed in a high-risk breast/ovarian cancer clinic: it is all about the tubes in BRCA mutation carriers. 61
30775416 2019
47
[Management of epithelial ovarian cancer. Short text drafted from the French joint recommendations of FRANCOGYN, CNGOF, SFOG, GINECO-ARCAGY and endorsed by INCa]. 61
30850152 2019
48
A patient-centered mobile health application to motivate use of genetic counseling among women with ovarian cancer: A pilot randomized controlled trial. 61
30718125 2019
49
TNM classification of gynaecological malignant tumours, eighth edition: changes between the seventh and eighth editions. 61
30668753 2019
50
Sectioning and extensively examining the fimbriated end (SEE-FIM) of the fallopian tube in routine practices, is it worth the effort? 61
30506766 2019

Variations for Fallopian Tube Carcinoma

Cosmic variations for Fallopian Tube Carcinoma:

9 (show top 50) (show all 683)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM87905773 TP53 ovary,NS,carcinoma,adenocarcinoma c.542G>A p.R181H 17:7675070-7675070 6
2 COSM87899223 TP53 ovary,NS,carcinoma,adenocarcinoma c.578A>T p.H193L 17:7674953-7674953 6
3 COSM87905366 TP53 ovary,NS,carcinoma,adenocarcinoma c.476C>T p.A159V 17:7675136-7675136 6
4 COSM87901171 TP53 ovary,NS,carcinoma,adenocarcinoma c.395A>G p.K132R 17:7675217-7675217 6
5 COSM145422024 TNFAIP3 ovary,NS,carcinoma,adenocarcinoma c.940G>A p.V314I 6:137877210-137877210 6
6 COSM91381505 SMAD4 ovary,NS,carcinoma,adenocarcinoma c.1051G>C p.D351H 18:51065518-51065518 6
7 COSM88349172 SMAD2 ovary,NS,carcinoma,adenocarcinoma c.785-1G>C p.? 18:47848688-47848688 6
8 COSM92365507 RET ovary,NS,carcinoma,adenocarcinoma c.3253A>G p.T1085A 10:43128177-43128177 6
9 COSM90833519 PTCH1 ovary,NS,carcinoma,adenocarcinoma c.3074G>A p.R1025H 9:95458107-95458107 6
10 COSM87152527 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.1034A>T p.N345I 3:179203764-179203764 6
11 COSM87132544 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.1636C>A p.Q546K 3:179218306-179218306 6
12 COSM87145727 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.3012G>T p.M1004I 3:179234169-179234169 6
13 COSM87139234 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.2725T>C p.F909L 3:179230062-179230062 6
14 COSM87133231 PIK3CA ovary,NS,carcinoma,adenocarcinoma c.263G>A p.R88Q 3:179199088-179199088 6
15 COSM97107326 NRAS ovary,NS,carcinoma,adenocarcinoma c.181C>A p.Q61K 1:114713909-114713909 6
16 COSM97107379 NRAS ovary,NS,carcinoma,adenocarcinoma c.35G>A p.G12D 1:114716126-114716126 6
17 COSM87804005 KRAS ovary,NS,carcinoma,adenocarcinoma c.35G>A p.G12D 12:25245350-25245350 6
18 COSM88586417 ERBB2 ovary,NS,carcinoma,adenocarcinoma c.2524G>A p.V842I 17:39725079-39725079 6
19 COSM86804346 EGFR ovary,NS,carcinoma,adenocarcinoma c.2099A>G p.N700S 7:55173958-55173958 6
20 COSM86804352 EGFR ovary,NS,carcinoma,adenocarcinoma c.2123A>G p.K708R 7:55173982-55173982 6
21 COSM86808602 EGFR ovary,NS,carcinoma,adenocarcinoma c.2597A>G p.E866G 7:55191846-55191846 6
22 COSM86751503 EGFR ovary,NS,carcinoma,adenocarcinoma c.2494C>T p.R832C 7:55191743-55191743 6
23 COSM86769580 EGFR ovary,NS,carcinoma,adenocarcinoma c.2173A>G p.T725A 7:55174032-55174032 6
24 COSM86757992 EGFR ovary,NS,carcinoma,adenocarcinoma c.2108T>C p.L703P 7:55173967-55173967 6
25 COSM86757673 EGFR ovary,NS,carcinoma,adenocarcinoma c.2174C>T p.T725M 7:55174033-55174033 6
26 COSM86757974 EGFR ovary,NS,carcinoma,adenocarcinoma c.2159C>T p.S720F 7:55174018-55174018 6
27 COSM86770841 EGFR ovary,NS,carcinoma,adenocarcinoma c.2481C>T p.Y827= 7:55191730-55191730 6
28 COSM86748127 EGFR ovary,NS,carcinoma,adenocarcinoma c.2573T>G p.L858R 7:55191822-55191822 6
29 COSM86751403 EGFR ovary,NS,carcinoma,adenocarcinoma c.2161G>A p.G721S 7:55174020-55174020 6
30 COSM86757983 EGFR ovary,NS,carcinoma,adenocarcinoma c.2232C>A p.I744= 7:55174769-55174769 6
31 COSM86761167 EGFR ovary,NS,carcinoma,adenocarcinoma c.2506C>A p.R836S 7:55191755-55191755 6
32 COSM86751510 EGFR ovary,NS,carcinoma,adenocarcinoma c.2604A>T p.E868D 7:55191853-55191853 6
33 COSM86780270 EGFR ovary,NS,carcinoma,adenocarcinoma c.2112G>A p.L704= 7:55173971-55173971 6
34 COSM86767926 EGFR ovary,NS,carcinoma,adenocarcinoma c.2122A>G p.K708E 7:55173981-55173981 6
35 COSM86755734 EGFR ovary,NS,carcinoma,adenocarcinoma c.2559C>T p.I853= 7:55191808-55191808 6
36 COSM86770885 EGFR ovary,NS,carcinoma,adenocarcinoma c.2165C>T p.A722V 7:55174024-55174024 6
37 COSM86805588 EGFR ovary,NS,carcinoma,adenocarcinoma c.2556G>T p.K852N 7:55191805-55191805 6
38 COSM88138689 ATM ovary,NS,carcinoma,adenocarcinoma c.1810C>T p.P604S 11:108252824-108252824 6
39 COSM97820944 AR ovary,NS,carcinoma,adenocarcinoma c.2179C>T p.R727C 23:67717483-67717483 6
40 COSM133536287 AKT1 ovary,NS,carcinoma,adenocarcinoma c.235C>A p.Q79K 14:104776711-104776711 6
41 COSM148939078 ovary,NS,carcinoma,adenocarcinoma c.2725T>C p.F909L 3:179230062-179230062 6
42 COSM111761369 ovary,NS,carcinoma,adenocarcinoma c.395A>G p.K132R 17:7675217-7675217 6
43 COSM142841902 ovary,NS,carcinoma,adenocarcinoma c.476C>T p.A159V 17:7675136-7675136 6
44 COSM122736483 ovary,NS,carcinoma,adenocarcinoma c.-2A>G p.? 17:7675217-7675217 6
45 COSM147950776 ovary,NS,carcinoma,adenocarcinoma c.*163A>G p.? 7:55174032-55174032 6
46 COSM111980548 ovary,NS,carcinoma,adenocarcinoma c.2462A>G p.E821G 7:55191846-55191846 6
47 COSM145024458 ovary,NS,carcinoma,adenocarcinoma c.425G>A p.R142H 17:7675070-7675070 6
48 COSM121879352 ovary,NS,carcinoma,adenocarcinoma c.-2A>G p.? 17:7675217-7675217 6
49 COSM139858573 ovary,NS,carcinoma,adenocarcinoma c.695-1G>C p.? 18:47848688-47848688 6
50 COSM147940767 ovary,NS,carcinoma,adenocarcinoma c.*164C>T p.? 7:55174033-55174033 6

Expression for Fallopian Tube Carcinoma

Search GEO for disease gene expression data for Fallopian Tube Carcinoma.

Pathways for Fallopian Tube Carcinoma

Pathways related to Fallopian Tube Carcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 51)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.83 VEGFA TP53 RAD51D PTEN PGR MYC
2
Show member pathways
13.72 VEGFA TP53 MYC MMP2 ESR1 ERBB2
3
Show member pathways
13.23 TP53 RAD51D RAD51C PARP2 PALB2 BRCA2
4
Show member pathways
13.01 VEGFA TP53 PTEN MYC ERBB2 CDKN1B
5
Show member pathways
12.99 TP53 RAD51D PTEN CDKN1B BRCA1 BARD1
6
Show member pathways
12.87 TP53 PTEN MYC ESR1 BRCA1 BARD1
7
Show member pathways
12.84 VEGFA TP53 PTEN PAX8 MYC ERBB2
8
Show member pathways
12.71 TP53 MYC ESR1 CDKN1B BRCA2 BRCA1
9
Show member pathways
12.64 VEGFA TP53 PTEN MYC ERBB2 CDKN1B
10
Show member pathways
12.58 TP53 PTEN PGR MYC ESR1 ERBB2
11 12.58 VEGFA TP53 PTEN PAX8 MYC MMP2
12
Show member pathways
12.52 TP53 PTEN MMP2 ESR1 ERBB2 CDKN1B
13 12.49 VEGFA TP53 PTEN MYC ERBB2 CDKN1B
14
Show member pathways
12.42 TP53 PTEN MYC CDKN1B BRCA1
15
Show member pathways
12.39 TP53 PTEN MYC CDKN1B
16 12.31 VEGFA TP53 MYC MMP2 ESR1 ERBB2
17 12.28 WT1 TP53 PAX8 MYC CDKN1B
18
Show member pathways
12.28 RAD51D RAD51C PALB2 BRCA2 BRCA1 BARD1
19
Show member pathways
12.26 TP53 PTEN MYC ERBB2 CDKN1B
20
Show member pathways
12.24 PGR MYC ESR1 CDKN1B BRCA1
21 12.21 VEGFA TP53 MYC MMP2
22 12.03 VEGFA TP53 MYC MMP2
23
Show member pathways
12.02 RAD51D RAD51C PALB2 BRCA2 BRCA1 BARD1
24 12.01 TP53 PTEN MYC CDKN1B
25 12.01 TP53 PTEN MYC ERBB2 CDKN1B
26
Show member pathways
11.92 VEGFA MYC ESR1 ERBB2
27 11.92 RAD51C PALB2 BRCA2 BRCA1
28 11.91 TP53 PTEN MYC CDKN1B
29 11.88 TP53 MYC CDKN1B BARD1
30
Show member pathways
11.85 TP53 BRCA2 BRCA1 BARD1
31 11.75 TP53 ERBB2 BRCA1
32 11.74 MYC CDKN1B BRCA1
33 11.74 TP53 PTEN MYC ERBB2
34 11.74 VEGFA TP53 MYC MMP2 ERBB2
35 11.71 PAX8 MYC CDKN1B
36 11.71 MYC ERBB2 CDKN1B
37 11.68 MYC ERBB2 CDKN1B BRCA1
38
Show member pathways
11.66 MYC MMP2 ERBB2 CDKN1B
39 11.65 WT1 PARP2 MYC ESR1 CDKN1B
40 11.62 TP53 PTEN MYC ERBB2 BRCA1
41 11.59 VEGFA TP53 MYC BRCA1
42 11.57 TP53 MYC CDKN1B
43 11.56 VEGFA MYC ESR1 CDKN1B
44
Show member pathways
11.53 ESR1 CDKN1B BRCA1
45 11.51 TP53 MYC BRCA1 BARD1
46 11.48 TP53 MYC ESR1
47 11.43 TP53 PTEN ESR1
48 11.41 MYC MMP2 ESR1 BRCA2
49 11.41 VEGFA TP53 PTEN MYC ESR1 BRCA2
50 11.3 TP53 BRCA1 BARD1

GO Terms for Fallopian Tube Carcinoma

Cellular components related to Fallopian Tube Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 10.28 WT1 VEGFA TP53 RAD51D RAD51C PTEN
2 nucleus GO:0005634 9.89 WT1 TP53 RAD51D RAD51C PTEN PGR
3 protein-containing complex GO:0032991 9.85 TP53 MYC ESR1 CDKN1B BRCA2 BRCA1
4 nucleoplasm GO:0005654 9.5 WT1 TP53 RAD51D RAD51C PTEN PGR
5 replication fork GO:0005657 9.43 TP53 RAD51D RAD51C
6 BRCA1-A complex GO:0070531 9.4 BRCA1 BARD1
7 Rad51B-Rad51C-Rad51D-XRCC2 complex GO:0033063 9.32 RAD51D RAD51C
8 BRCA1-BARD1 complex GO:0031436 9.16 BRCA1 BARD1

Biological processes related to Fallopian Tube Carcinoma according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.13 WT1 VEGFA TP53 PGR PAX8 MYC
2 regulation of transcription by RNA polymerase II GO:0006357 10.09 WT1 VEGFA TP53 MYC ESR1 ERBB2
3 positive regulation of transcription, DNA-templated GO:0045893 10.04 WT1 TP53 PAX8 MYC ESR1 BRCA2
4 positive regulation of gene expression GO:0010628 9.95 WT1 VEGFA TP53 PTEN MYC ERBB2
5 heart development GO:0007507 9.91 WT1 TP53 PTEN ERBB2 CDKN1B
6 protein deubiquitination GO:0016579 9.91 TP53 PTEN MYC ESR1 BRCA1 BARD1
7 cell cycle arrest GO:0007050 9.87 TP53 MYC CDKN1B BARD1
8 DNA repair GO:0006281 9.87 RAD51D RAD51C PARP2 PALB2 BRCA2 BRCA1
9 cellular response to hypoxia GO:0071456 9.86 VEGFA TP53 PTEN MYC
10 positive regulation of epithelial cell proliferation GO:0050679 9.79 VEGFA MYC ERBB2
11 double-strand break repair GO:0006302 9.78 TP53 PARP2 BRCA2 BRCA1
12 branching involved in ureteric bud morphogenesis GO:0001658 9.77 WT1 PAX8 MYC
13 DNA recombination GO:0006310 9.77 RAD51D RAD51C PALB2 BRCA2 BRCA1
14 response to gamma radiation GO:0010332 9.71 TP53 MYC BRCA2
15 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.64 TP53 ESR1
16 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.64 TP53 ESR1
17 telomere maintenance via recombination GO:0000722 9.63 RAD51C BRCA2
18 protein K6-linked ubiquitination GO:0085020 9.63 BRCA1 BARD1
19 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.63 TP53 BRCA2 BRCA1
20 cellular response to gonadotropin stimulus GO:0071371 9.62 WT1 PAX8
21 positive regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061419 9.61 VEGFA TP53
22 metanephric S-shaped body morphogenesis GO:0072284 9.61 WT1 PAX8
23 metanephric epithelium development GO:0072207 9.6 WT1 PAX8
24 positive regulation of DNA methylation GO:1905643 9.58 WT1 MYC
25 chordate embryonic development GO:0043009 9.58 BRCA2 BRCA1
26 chromosome organization GO:0051276 9.56 TP53 RAD51D MYC BRCA2
27 negative regulation of apoptotic process GO:0043066 9.56 WT1 VEGFA TP53 PTEN PALB2 MYC
28 double-strand break repair via homologous recombination GO:0000724 9.55 RAD51D RAD51C PALB2 BRCA2 BRCA1
29 cellular response to DNA damage stimulus GO:0006974 9.28 TP53 RAD51D RAD51C PARP2 PALB2 MYC

Molecular functions related to Fallopian Tube Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.21 WT1 VEGFA TP53 RAD51D RAD51C PTEN
2 zinc ion binding GO:0008270 9.85 WT1 TP53 PGR MMP2 ESR1 BRCA1
3 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.8 TP53 PGR PAX8 MYC ESR1
4 identical protein binding GO:0042802 9.76 VEGFA TP53 PTEN PGR ESR1 ERBB2
5 transcription regulatory region DNA binding GO:0044212 9.73 WT1 TP53 PAX8 BRCA1
6 enzyme binding GO:0019899 9.72 TP53 PTEN PGR ESR1 BRCA1
7 protein phosphatase binding GO:0019903 9.63 TP53 ERBB2 CDKN1B
8 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.43 WT1 TP53 PGR PAX8 MYC ESR1
9 DNA binding GO:0003677 9.4 WT1 TP53 RAD51D RAD51C PGR PAX8

Sources for Fallopian Tube Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....